Terms: = Cervical cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Clinical Outcome
3 results:
1. Negative Expression of CPSF2 Predicts a Poorer clinical outcome in Patients with Papillary Thyroid Carcinoma.
Sung TY; Kim M; Kim TY; Kim WG; Park Y; Song DE; Park SY; Kwon H; Choi YM; Jang EK; Jeon MJ; Shong YK; Hong SJ; Kim WB
Thyroid; 2015 Sep; 25(9):1020-5. PubMed ID: 26148673
[TBL] [Abstract] [Full Text] [Related]
2. Efficient detection of the V600E mutation of the braf gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography.
Gong RX; Gong YP; Yang J; Wei T; Li-Ling J; Zhu JQ
Genet Mol Res; 2013 Oct; 12(4):4990-7. PubMed ID: 24301760
[TBL] [Abstract] [Full Text] [Related]
3. Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a braf V600E-prevalent papillary thyroid cancer population.
Yim JH; Kim WG; Jeon MJ; Han JM; Kim TY; Yoon JH; Hong SJ; Song DE; Gong G; Shong YK; Kim WB
Thyroid; 2014 Apr; 24(4):689-94. PubMed ID: 24124924
[TBL] [Abstract] [Full Text] [Related]
